TDP-43 impairs sleep in Drosophila through Ataxin-2 -dependent metabolic disturbance.
Alexandra E PerlegosJaclyn DurkinSamuel J BelferAnyara RodriguezOksana ShcherbakovaKristen ParkHang Ngoc Bao LuongNancy M BoniniMatthew S KayserPublished in: Science advances (2024)
Neurodegenerative diseases such as amyotrophic lateral sclerosis and frontotemporal dementia are associated with substantial sleep disruption, which may accelerate cognitive decline and brain degeneration. Here, we define a role for trans-activation response element (TAR) DNA binding protein 43 (TDP-43), a protein associated with human neurodegenerative disease, in regulating sleep using Drosophila . Expression of TDP-43 severely disrupts sleep, and the sleep deficit is rescued by Atx2 knockdown. Brain RNA sequencing revealed that Atx2 RNA interference regulates transcripts enriched for small-molecule metabolic signaling in TDP-43 brains. Focusing on these Atx2 -regulated genes, we identified suppressors of the TDP-43 sleep phenotype enriched for metabolism pathways. Knockdown of Atx2 or treatment with rapamycin attenuated the sleep phenotype and mitigated the disruption of small-molecule glycogen metabolism caused by TDP-43. Our findings provide a connection between toxicity of TDP-43 and sleep disturbances and highlight key aspects of metabolism that interplay with TDP-43 toxicity upon Atx2 rescue.
Keyphrases
- amyotrophic lateral sclerosis
- small molecule
- sleep quality
- physical activity
- cognitive decline
- binding protein
- endothelial cells
- single cell
- protein protein
- mild cognitive impairment
- white matter
- depressive symptoms
- gene expression
- poor prognosis
- brain injury
- resting state
- genome wide
- single molecule
- blood brain barrier
- functional connectivity
- cerebral ischemia